Article Text

Download PDFPDF
Randomised controlled trial
In patients hospitalised with acute heart failure, nesiritide, compared with placebo, is not associated with improvements in dyspnoea or 30-day rehospitalisation or mortality
  1. Sacha P Salzberg
  1. Clinic for Cardiovascular Surgery, University Hospital, Zurich, Switzerland
  1. Correspondence to Sacha P Salzberg
    Clinic for Cardiovascular Surgery, University Hospital, Raemistreet 100, Zurich 8091, Switzerland; sacha.salzberg{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


In 2001 the FDA approved nesiritide for the treatment of acutely decompensated heart failure. As a potent intravenous vasodilator, nesiritide reduces cardiac filling pressures leading to symptomatic improvement in patients with acutely decompensated heart failure.1,,4 However, this drug remains heavily debated even years after its approval, mainly because of a lack of substantial long-term safety data.5 In light of this evidence, the manufacturer gathered a panel of experts in 2005 in order to address this issue. One of the recommendations of the panel was to conduct a clinical trial on …

View Full Text


  • Competing interests None.